Sean A. Reed
Associate
Dr. Sean Reed is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice is focused on intellectual property matters related to chemistry, chemical biology, and pharmaceuticals.
Prior to joining the firm, Sean was an NIH postdoctoral research fellow at the Scripps Research Institute, where he gained significant experience in the synthetic biology field. His work focused on the incorporation of unnatural amino acids into thiopeptide antibiotics and the creation of reduced amino acid organisms. Previously, he completed his doctoral degree at the University of Illinois, where his dissertation focused on the development and application of new carbon-hydrogen bond activation reactions to streamline the synthesis of pharmaceutical intermediates and diversify natural product scaffolds.
Experience
Dr. Sean Reed is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice is focused on intellectual property matters related to chemistry, chemical biology, and pharmaceuticals.
Prior to joining the firm, Sean was an NIH postdoctoral research fellow at the Scripps Research Institute, where he gained significant experience in the synthetic biology field. His work focused on the incorporation of unnatural amino acids into thiopeptide antibiotics and the creation of reduced amino acid organisms. Previously, he completed his doctoral degree at the University of Illinois, where his dissertation focused on the development and application of new carbon-hydrogen bond activation reactions to streamline the synthesis of pharmaceutical intermediates and diversify natural product scaffolds.
Education
- J.D., University of San Diego School of Law, 2022
- Ph.D., Chemistry, University of Illinois at Urbana-Champaign, 2012
- B.S., Chemistry and Psychology, Iowa State University, 2005
Associations and Memberships
- Member, San Diego Intellectual Property Law Association
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., University of San Diego School of Law, 2022
- Ph.D., Chemistry, University of Illinois at Urbana-Champaign, 2012
- B.S., Chemistry and Psychology, Iowa State University, 2005
Associations and Memberships
- Member, San Diego Intellectual Property Law Association
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Select Publications
- Co-author with A. Mehta, H. Li, L. Supekova, T. Javahishvili, and P. Schultz, "Replacement of 2'-deoxycytidine by 2'-deoxycytidine Analogs in the E. coli Genome," 138(43) Journal of the American Chemical Society 14230-3, 2016
- Co-author with A. Mehta, H. Li, L. Supekova, T. Javahishvili, and P. Schultz, "Replacement of Nucleosides by a Modified Base in the E. coli Genome," 138(23) Journal of the American Chemical Society 7272-5, 2016
- Co-author with X. Luo, C. Zambaldo, T. Liu, Y. Zhang, W. Xuan, C. Wang, P. Yang, R.E. Wang, T. Javahishvilli, P. Schultz, and T. Young, "Recombinant Thiopeptides Containing Noncanonical Amino Acids," 113(13) Proceedings of the National Academy of Sciences 3615-20, 2016
- Co-author with T. Liu, Y. Wang, X. Luo, J. Li, H. Xiao, T. Young, and P. Schultz, "Enhancing Protein Stability with Extended Disulfide Bonds," 113(21) Proceedings of the National Academy of Sciences 5910-5, 2016
- Co-author with H. Xiao, F. Nasertorabi, S.H. Choi, G. Han, R. Stevens, and P. Schultz, "Exploring the potential impact of an expanded genetic code on protein function," 112(22) Proceedings of the National Academy of Sciences 6961-6, 2015
- Coauthor with H. Xiao, F. Peters, P.Y. Yang, J. Chittuluru, and P. Schultz, "Genetic incorporation of histidine derivatives using an engineered pyrrolysyl-tRNA synthetase," 9(5) ACS Chemical Biology 1092-6, 2014
- Co-author with M. Bigi and M. White, "Directed metal(oxo) aliphatic C—H hydroxylation: Overriding substrate bias," 134(23) Journal of the American Chemical Society 9721-6, 2012
- Co-author with M. Bigi and M. White, "Diverting non-haem iron catalysed aliphatic C—H hydroxylations towards desaturations," 3 Nature Chemistry 216-22, 2011
- Co-author with A. Mazzotti and M. White, "A Catalytic, Brønsted Base Strategy for Intermolecular Allylic C—H Amination," 131(33) Journal of the American Chemical Society 11701-6, 2009
- Co-author with M. White, "Catalytic, Intermolecular Linear Allylic C—H Amination via Hetereobimetallic Catalysis," 130(11) Journal of the American Chemical Society 3316-8, 2008
Insights
Select Publications
- Co-author with A. Mehta, H. Li, L. Supekova, T. Javahishvili, and P. Schultz, "Replacement of 2'-deoxycytidine by 2'-deoxycytidine Analogs in the E. coli Genome," 138(43) Journal of the American Chemical Society 14230-3, 2016
- Co-author with A. Mehta, H. Li, L. Supekova, T. Javahishvili, and P. Schultz, "Replacement of Nucleosides by a Modified Base in the E. coli Genome," 138(23) Journal of the American Chemical Society 7272-5, 2016
- Co-author with X. Luo, C. Zambaldo, T. Liu, Y. Zhang, W. Xuan, C. Wang, P. Yang, R.E. Wang, T. Javahishvilli, P. Schultz, and T. Young, "Recombinant Thiopeptides Containing Noncanonical Amino Acids," 113(13) Proceedings of the National Academy of Sciences 3615-20, 2016
- Co-author with T. Liu, Y. Wang, X. Luo, J. Li, H. Xiao, T. Young, and P. Schultz, "Enhancing Protein Stability with Extended Disulfide Bonds," 113(21) Proceedings of the National Academy of Sciences 5910-5, 2016
- Co-author with H. Xiao, F. Nasertorabi, S.H. Choi, G. Han, R. Stevens, and P. Schultz, "Exploring the potential impact of an expanded genetic code on protein function," 112(22) Proceedings of the National Academy of Sciences 6961-6, 2015
- Coauthor with H. Xiao, F. Peters, P.Y. Yang, J. Chittuluru, and P. Schultz, "Genetic incorporation of histidine derivatives using an engineered pyrrolysyl-tRNA synthetase," 9(5) ACS Chemical Biology 1092-6, 2014
- Co-author with M. Bigi and M. White, "Directed metal(oxo) aliphatic C—H hydroxylation: Overriding substrate bias," 134(23) Journal of the American Chemical Society 9721-6, 2012
- Co-author with M. Bigi and M. White, "Diverting non-haem iron catalysed aliphatic C—H hydroxylations towards desaturations," 3 Nature Chemistry 216-22, 2011
- Co-author with A. Mazzotti and M. White, "A Catalytic, Brønsted Base Strategy for Intermolecular Allylic C—H Amination," 131(33) Journal of the American Chemical Society 11701-6, 2009
- Co-author with M. White, "Catalytic, Intermolecular Linear Allylic C—H Amination via Hetereobimetallic Catalysis," 130(11) Journal of the American Chemical Society 3316-8, 2008
Recent Insights
Client Highlights
Wilson Sonsini Advises Enlaza Therapeutics on IP Matters Related to $100 Million Series A
On April 30, 2024, Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it successfully closed a $100 million Series A financing. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the Series A and represents the company in patent strategy and prosecution matters.
Learn More
Client Highlights
Firm Advises Belite Bio on IP Matters Related to $36 Million IPO
On April 28, 2022, Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of its initial public offering of six million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00. Each ADS represents one ordinary share of Belite. In addition, Belite has granted the underwriters a 30-day option to purchase an additional 900,000 ADSs at the initial public offering price, less underwriting discounts and commissions. Lin Bioscience International Ltd., the company’s principal shareholder, agreed to purchase $15.0 million of ADSs in the offering. Wilson Sonsini Goodrich & Rosati advised Belite Bio on intellectual property matters related to the transaction.
In connection with the offering, Belite’s ADSs have been approved for listing on the Nasdaq Capital Market. The ADSs began trading on April 29, 2022, under the ticker symbol “BLTE.” The offering closed on May 3, 2022. The gross proceeds to Belite from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $36 million. Belite expects to use the net proceeds to fund the Phase 3 clinical trial of its lead candidate, LBS-008, for Stargardt disease (an inherited juvenile form of macular degeneration) and for further clinical development of LBS-008 for dry age-related macular degeneration (AMD), working capital, and other general corporate purposes.
Founded in 2016, San Diego, California-based Belite Bio targets untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Wilson Sonsini has handled all IP matters for Belite since the company’s inception.
The Wilson Sonsini team advising Belite on intellectual property matters related to the IPO was led by Deborah Smith, Sean Reed, and Matt Bresnahan.
For more information, please see Belite’s press release.
In connection with the offering, Belite’s ADSs have been approved for listing on the Nasdaq Capital Market. The ADSs began trading on April 29, 2022, under the ticker symbol “BLTE.” The offering closed on May 3, 2022. The gross proceeds to Belite from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $36 million. Belite expects to use the net proceeds to fund the Phase 3 clinical trial of its lead candidate, LBS-008, for Stargardt disease (an inherited juvenile form of macular degeneration) and for further clinical development of LBS-008 for dry age-related macular degeneration (AMD), working capital, and other general corporate purposes.
Founded in 2016, San Diego, California-based Belite Bio targets untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Wilson Sonsini has handled all IP matters for Belite since the company’s inception.
The Wilson Sonsini team advising Belite on intellectual property matters related to the IPO was led by Deborah Smith, Sean Reed, and Matt Bresnahan.
For more information, please see Belite’s press release.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.